Literature DB >> 27861807

Identification of HLA-DRB1*09:01-restricted Mycobacterium tuberculosis CD4+ T-cell epitopes.

Su-Dong Liu1, Shi-Meng Zhang1, Hui Wang1, Jian-Chun He1, Xiao-Fan Yang1, Xia-Lin Du1, Li Ma1,2.   

Abstract

CD4+ T cells play an essential role in protection against Mycobacterium tuberculosis (MTB) infection. We identified three HLA-DRB1*09:01-restricted CD4+ T-cell epitopes derived from the dominant secreted MTB antigens 38 kDa (Rv3804c) and Ag85A (Rv0934). The antigens were screened for epitopes by in silico prediction programs and analysis of IFN-γ induction in the peripheral blood mononuclear cells (PBMCs) from TB patients. In response to three of the high-affinity predicted epitopes derived from 38 kDa and Ag85A, CD4+ T cells from HLA-DRB1*09:01 TB patients were stimulated to produce IFN-γ and Tumor Necrosis Factor (TNF)-α. The three epitopes were also found to induce the proliferation of CD4+ T cells by carboxyfluorescein succinimidyl ester-diluted assays. These HLA-DRB1*09:01-restricted CD4+ T-cell epitopes facilitate analysis of the role of 38 kDa- and Ag85A-specific T cells in MTB infection and pave way for the design of vaccines against tuberculosis.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  zzm321990MTBzzm321990; CD4+ T-cell epitope; IFN-γ; Proliferation; active TB patient; class II restriction

Mesh:

Substances:

Year:  2016        PMID: 27861807     DOI: 10.1002/1873-3468.12478

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  [Association between HLA-A and HLA-DRB1 allele polymorphisms and susceptibility to tuberculosis in southern Chinese population].

Authors:  Chunxin Liao; Jiahui Yang; Jinli Wang; Xialin Du; Ruining Wang; Shimeng Zhang; Wenting He; Qian Wen; Li Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

2.  Factors associated with differential T cell responses to antigens ESAT-6 and CFP-10 in pulmonary tuberculosis patients.

Authors:  Shengsheng Liu; Meiying Wu; Ertai A; Shucai Wu; Shujun Geng; Zhihui Li; Mingwu Li; Liang Li; Yu Pang; Wanli Kang; Shenjie Tang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.